Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

NCT03847246 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis b

Interventions

DRUG: Baraclude® tablets,1.0 mg
DRUG: Entecavir tablets,1.0 mg

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.